James B. Tananbaum, Director, 10% Owner at Kinnate Biopharma Inc. (KNTE), bought 3,560,000 shares at $2.80 ($10.0M) on 2023-05-08, disclosed to the SEC on 2023-05-10.
Open-market purchase of $10.0M KNTE by Director, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $2.80 | 229,044 | $641K | 6.4% |
| 2 | $2.80 | 229,044 | $641K | 6.4% |
| 3 | $2.80 | 1,550,956 | $4.3M | 43.6% |
| 4 | $2.80 | 1,550,956 | $4.3M | 43.6% |
| Total | $2.80 avg | 3,560,000 | $10.0M | 100% |
| Filing → |
| ALMS | BUY | 2025-11-25 | $1.1M | — | Filing → |
| ALMS | BUY | 2025-11-19 | $3.8M | — | Filing → |
| ALMS | BUY | 2025-05-06 | $202K | — | Filing → |